Vitamin D Levels in Women with Systemic Lupus Erythematosus and Fibromyalgia

A. MARGRIET HUISMAN, KEVIN P. WHITE, ALE ALGRA, MANFRED HARTH, REINHOLD VIETH, JOHANNES W.G. JACOBS, JOHANNES W.J. BIJLSMA, and DAVID A. BELL

ABSTRACT. Objective. Many patients with systemic lupus erythematosus (SLE) and fibromyalgia (FM) may spend less time exposed to the sun than healthy individuals and thus might have low vitamin D levels. It is known that hydroxychloroquine (HCQ) inhibits conversion of 25(OH)- to 1,25(OH)₂-vitamin D both in vitro and in patients with sarcoidosis. We assessed winter serum 25(OH)- and 1,25(OH)₂-vitamin D levels in patients with SLE and FM.

Methods. We recruited 25 consecutive female SLE and 25 female FM patients in London, Ontario, between January and March 2000. Subjects completed a brief questionnaire. Serum levels of 25(OH)-, 1,25(OH)₂-vitamin D, and parathyroid hormone (PTH) were measured.

Results. In SLE patients mean 25(OH)-vitamin D was 46.5 nmol/l and mean 1,25(OH)₂-vitamin D was 74.4 pmol/l. In FM patients these means were 51.5 nmol/l and 90.1 pmol/l, respectively. Serum 25(OH)-vitamin D levels did not significantly differ between SLE and FM patients, nor after adjusting for age and vitamin D, milk consumption, and sun block use. In 14 of the SLE patients and 12 of the FM patients 25(OH)-vitamin D levels < 50 nmol/l were found. SLE patients not using vitamin D supplements had lower 25(OH)-vitamin D levels than those who did. 1,25(OH)₂-vitamin D tended to be lower in the SLE compared to the FM patients. This difference could be attributed to HCQ use: HCQ users (n = 17) had lower 1,25(OH)₂-vitamin D levels than nonusers (n = 33); the mean adjusted difference was 24.4 pmol/l (95% CI 2.8–49.9).

Conclusion. Half the SLE and FM patients had 25(OH)-vitamin D levels < 50 nmol/l, a level at which PTH stimulation occurs. Our data suggest that in SLE patients HCQ might inhibit conversion of 25(OH)-vitamin D to 1,25(OH)₂-vitamin D. (J Rheumatol 2001;28:2535–9)

Key Indexing Terms:
25(OH)-VITAMIN D  1,25(OH)₂-VITAMIN D  FIBROMYALGIA
SYSTEMIC LUPUS ERYTHEMATOSUS  HYDROXYCHLOROQUINE
considered deficient\(^9\). PTH levels approach their lowest range when serum 25(OH)-vitamin D level is \(> 70\) nmol/l\(^{7,10-12}\). Heaney\(^{13}\) and Vieth\(^{14}\) argued that individuals exposed to the sun in lower latitudes always have serum 25(OH)-vitamin D > 100 nmol/l, reflecting a healthy threshold to prevent pathophysiological effects on bone.

Patients with lupus often seek to prevent sun exposure by wearing a hat or scarf and by using sun screen. Recently, Redlich, \textit{et al.} reported a high frequency of osteoporosis in premenopausal women with SLE\(^{15}\). Hence vitamin D deficiency should be prevented in patients with SLE, whose bone likely is already made more vulnerable by disease activity and prednisone use. Some patients with SLE appear to be aware of the risk of vitamin D insufficiency and use vitamin D supplements.

We undertook this pilot study to measure 25(OH)-vitamin D and 1,25(OH)\(_2\)-vitamin D levels and to relate these to milk intake and vitamin D supply. We also compared the vitamin D levels of lupus patients with those of patients with fibromyalgia (FM). In addition we studied if hydroxychloroquine (HCQ), used by many SLE patients as an immunosuppressant, lowered the conversion of 25(OH)-vitamin D to 1,25(OH)\(_2\)-vitamin D. Because of this effect HCQ is used in patients with sarcoidosis to treat hypercalcemia\(^{16-18}\).

**MATERIALS AND METHODS**

**Subjects.** All subjects were recruited from the outpatient rheumatology clinic of the university campus of the London Health Sciences Centre in London, Ontario. In January, February, and March 2000, consecutive patients with lupus and primary FM were given an information letter and asked to participate. Inclusion criteria were female sex, age 18–65 years, Caucasian race, and either SLE or FM in accord with the American College of Rheumatology classification criteria\(^{19,20}\). Any potential subject who met both sets of classification criteria (for SLE and FM) was excluded, as were patients with liver or kidney dysfunction defined as any abnormality in serum levels of alkaline phosphatase, aspartate or alanine aminotransferase, blood urea nitrogen or creatinine. All subjects completed a health questionnaire asking about medication, vitamin D supplementation, diet, life habits, previous operations, and weight loss.

**Laboratory assays.** Liver and kidney function were measured as well as serum ionized calcium, phosphate, and alkaline phosphatase. Intact serum PTH was measured by the immunoradiometric method (IRMA) using kits provided by Nichols Institute Diagnostics (San Juan Capistrano, CA, USA; normal values 10–60 ng/l). Serum 25(OH)-vitamin D was measured by the Dia Sorin radioimmunoassay (Dia Sorin, Stillwater, MN, USA; normal values 25–250 nmol/l). The method for 1,25(OH)\(_2\)-vitamin D measurement was the calf thymus radio-receptor assay with cartridge extraction of serum that was prelabelled with a tracer amount of 1,25(OH)\(_2\)-vitamin D to monitor for recovery. Normal values for 1,25(OH)\(_2\)-vitamin D are 40 to 140 pmol/l. The vitamin D measurements were done at Mount Sinai Hospital in Toronto.

**Data analysis.** Using Student’s t test for unpaired groups, group mean vitamin D levels (both 25(OH)- and 1,25(OH)\(_2\)-vitamin D) were compared between patients with FM and SLE. Data are presented in Table 2 as mean difference and corresponding 95% confidence intervals (CI). In multivariate linear regression analysis, differences were adjusted for other known determinants of vitamin D levels including age, vitamin D supplement and milk consumption, and sun block use. Similar analyses were performed comparing patients taking and not taking HCQ.

**RESULTS**

Table 1 displays the characteristics of the 25 women with FM and 25 with SLE. The patients with FM were, on average, 5 years older than the patients with SLE. SLE patients used more drugs that potentially could interfere with vitamin D metabolism, but their intake of vitamin D also tended to be higher than in women with FM. SLE patients more frequently used sun block than FM patients, even during the winter months in which the study was conducted. Liver function, kidney function, serum ionized calcium and alkaline phosphatase all were within normal limits. Serum phosphate was low in 2 patients.

Table 2 summarizes the vitamin D levels for 25(OH)- and 1,25(OH)\(_2\)-vitamin D by disease category and use of HCQ. There was no significant difference between FM and SLE patients with respect to 25(OH)-vitamin D levels, even after adjusting for age and vitamin D supplement, milk, and sun block use. Twelve FM patients (48%) and 14 SLE patients (58%) had 25(OH)-vitamin D levels < 50 nmol/l. SLE patients not taking vitamin D supplements had lower 25(OH)-vitamin D levels than those who did; the mean difference was 21.8 nmol/l (95% CI 5.8–38.0). Seventy-seven percent of the SLE patients not taking vitamin D supplements had a 25(OH)-vitamin D level < 50 nmol/l (n = 14).

Figure 1 illustrates 1,25(OH)\(_2\)-vitamin D levels in SLE patients taking and not taking HCQ, and in patients with FM, none of whom used HCQ. Because the 1,25(OH)\(_2\)-vitamin D levels were virtually the same in the SLE and FM patients not taking HCQ, these 2 subject groups were combined. The mean difference in 1,25(OH)\(_2\)-vitamin D levels between HCQ users and all nonusers (SLE and FM) was statistically significant: 29.1 pmol/l (95% CI 11.2–46.9). This difference decreased slightly after adjusting for age and vitamin D supplement, milk, and sun block use to 24.4 pmol/l (95% CI 2.8–45.9). Three SLE patients using HCQ had 1,25(OH)\(_2\)-vitamin D levels < 40 pmol/l. However, their 25(OH)-vitamin D levels were 49, 50, and 66 nmol/l.

<table>
<thead>
<tr>
<th>Table 1. Clinical characteristics of the patients at enrollment.</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Fibromyalgia, n = 25</strong></td>
</tr>
<tr>
<td>Age, yrs (SD)</td>
</tr>
<tr>
<td>Drug use</td>
</tr>
<tr>
<td>Hydroxychloroquine</td>
</tr>
<tr>
<td>Prednisone (5–14 mg/day)</td>
</tr>
<tr>
<td>Azathioprine</td>
</tr>
<tr>
<td>Vitamin D supplement (\geq 400) (IU/day)</td>
</tr>
<tr>
<td>Calcium supplement (\geq 500) (mg/day)</td>
</tr>
<tr>
<td>Dietary vitamin D intake (\geq 250) (cc/milk/day)(^*)</td>
</tr>
<tr>
<td>Exposure to daylight &gt; 30 min/day</td>
</tr>
<tr>
<td>Sun block use (factor (\geq 20))</td>
</tr>
</tbody>
</table>

\(^1\) Data in parentheses are percentages. * In Canada 250 cc standard milk is enriched with 90 IU vitamin D.
The mean PTH level in patients with 25(OH)-vitamin D levels < 50 nmol/l (n = 23) was 41.0 (± 21.2) ng/l and in those with levels > 50 nmol/l (n = 23) it was 26.7 (± 9.8) ng/l; the mean difference was 14.3 ng/l (95% CI 4.4–24.1).

**DISCUSSION**

During winter about half our patients with SLE and FM had 25(OH)-vitamin D levels less than 50 nmol/l. There was no significant difference in mean 25(OH)-vitamin D levels in SLE and FM patients. The mean levels of 25(OH)-vitamin D in the SLE and FM patients are typical winter averages for healthy adults. We observed PTH stimulation in subjects with 25(OH)-vitamin D levels < 50 nmol/l, as reported. The literature about vitamin D levels in SLE and FM is sparse. In 21 patients with SLE 25(OH)-vitamin D levels were lower than in healthy volunteers. In another study of 12 adolescent patients with SLE, 7 were found to have subnormal 1,25(OH)₂-vitamin D levels. The complaints of patients with FM resemble those of patients with vitamin D deficiency. Reginato, et al described 2 patients, initially diagnosed with FM, who eventually appeared to be suffering from osteomalacia due to vitamin D deficiency with secondary FM. Thus it may be useful to measure vitamin D levels in patients with FM.

Three-quarters of the patients with SLE in our study who did not take vitamin D supplements had 25(OH)-vitamin D levels < 50 nmol/l. In these patients, who also have other risk factors for osteomalacia such as disease activity and the use of prednisone, 25(OH)-vitamin D should be measured, and if lower than 50 nmol/l these patients should be advised to take vitamin D on a daily basis, especially during winter months in colder climates. Over-the-counter multivitamins in general contain up to 400 IU of vitamin D per tablet. We asked patients about their use of multivitamins. Many did take multivitamins, but not on a daily basis. If they do use multivitamins without further vitamin D supplementation, they may not be protected from having low vitamin D levels in winter.

Hydroxychloroquine, used by many patients with SLE as an immunosuppressant, is also prescribed in patients with sarcoidosis to treat hypercalcemia. This effect is probably mediated by inhibition of the conversion of 25(OH)-vitamin D to 1,25(OH)₂-vitamin D. Theoretically this effect might also be achieved by influence of HCQ on the disease process itself. Our study shows lower 1,25(OH)₂-vitamin D levels in HCQ users compared to nonusers.

The mean PTH level in patients with 25(OH)-vitamin D levels < 50 nmol/l (n = 23) was 41.0 (± 21.2) ng/l and in those with levels > 50 nmol/l (n = 23) it was 26.7 (± 9.8) ng/l; the mean difference was 14.3 ng/l (95% CI 4.4–24.1).

**DISCUSSION**

During winter about half our patients with SLE and FM had 25(OH)-vitamin D levels less than 50 nmol/l. There was no significant difference in mean 25(OH)-vitamin D levels in SLE and FM patients. The mean levels of 25(OH)-vitamin D in the SLE and FM patients are typical winter averages for healthy adults. We observed PTH stimulation in subjects with 25(OH)-vitamin D levels < 50 nmol/l, as reported. The literature about vitamin D levels in SLE and FM is sparse. In 21 patients with SLE 25(OH)-vitamin D levels were lower than in healthy volunteers. In another study of 12 adolescent patients with SLE, 7 were found to have subnormal 1,25(OH)₂-vitamin D levels. The complaints of patients with FM resemble those of patients with vitamin D deficiency. Reginato, et al described 2 patients, initially diagnosed with FM, who eventually appeared to be suffering from osteomalacia due to vitamin D deficiency with secondary FM. Thus it may be useful to measure vitamin D levels in patients with FM.

Three-quarters of the patients with SLE in our study who did not take vitamin D supplements had 25(OH)-vitamin D levels < 50 nmol/l. In these patients, who also have other risk factors for osteomalacia such as disease activity and the use of prednisone, 25(OH)-vitamin D should be measured, and if lower than 50 nmol/l these patients should be advised to take vitamin D on a daily basis, especially during winter months in colder climates. Over-the-counter multivitamins in general contain up to 400 IU of vitamin D per tablet. We asked patients about their use of multivitamins. Many did take multivitamins, but not on a daily basis. If they do use multivitamins without further vitamin D supplementation, they may not be protected from having low vitamin D levels in winter.

Hydroxychloroquine, used by many patients with SLE as an immunosuppressant, is also prescribed in patients with sarcoidosis to treat hypercalcemia. This effect is probably mediated by inhibition of the conversion of 25(OH)-vitamin D to 1,25(OH)₂-vitamin D. Theoretically this effect might also be achieved by influence of HCQ on the disease process itself. Our study shows lower 1,25(OH)₂-vitamin D levels in HCQ users compared to nonusers.

### Table 2. Vitamin D and parathyroid hormone levels according to patient characteristics.

<table>
<thead>
<tr>
<th></th>
<th>Fibromyalgia*, n = 25</th>
<th>SLE No HCQ, n = 8</th>
<th>SLE HCQ, n = 17</th>
</tr>
</thead>
<tbody>
<tr>
<td>Serum 25(OH)-vitamin D, nmol/l (SD)</td>
<td>51.5 (17.1)</td>
<td>43.5 (20.0)</td>
<td>48.0 (20.0)</td>
</tr>
<tr>
<td>&lt; 25 nmol/l (%)</td>
<td>1 (4)</td>
<td>1 (13)</td>
<td>3 (18)</td>
</tr>
<tr>
<td>&lt; 37.5 nmol/l (%)</td>
<td>6 (24)</td>
<td>4 (50)</td>
<td>5 (31)</td>
</tr>
<tr>
<td>&lt; 50 nmol/l (%)</td>
<td>12 (48)</td>
<td>6 (75)</td>
<td>8 (50)</td>
</tr>
<tr>
<td>Crude difference, FM – SLE (95% CI)</td>
<td>5.0 (–5.6 to 15.6)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Adjusted** difference, FM – SLE (95% CI)</td>
<td>7.8 (–4.7 to 20.3)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Crude difference HCQ, no – yes (95% CI)</td>
<td>1.5 (–9.8 to 12.9)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Adjusted** difference HCQ, no – yes (95% CI)</td>
<td>0.2 (–12.9 to 12.5)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Serum 1,25(OH)₂-vitamin D, pmol/l (SD)</td>
<td>90.1 (29.5)</td>
<td>0 (0)</td>
<td>63.1 (26.4)</td>
</tr>
<tr>
<td>&lt; 40 pmol/l (%)</td>
<td>0 (0)</td>
<td>0 (0)</td>
<td>3 (18)</td>
</tr>
<tr>
<td>Crude difference, FM – SLE (95% CI)</td>
<td>15.8 (–2.4 to 33.9)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Adjusted** difference, FM – SLE (95% CI)</td>
<td>6.8 (–16.5 to 29.7)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Crude difference HCQ, no – yes (95% CI)</td>
<td>29.1 (11.2 to 46.9)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Adjusted** difference HCQ, no – yes (95% CI)</td>
<td>24.4 (2.8 to 45.9)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Serum parathyroid hormone, ng/l (SD)</td>
<td>34.5 (12.8)</td>
<td>32.1 (16.0)</td>
<td>33.6 (25.1)</td>
</tr>
</tbody>
</table>

* No patient with FM used HCQ. ** Adjusted for age and vitamin D supplement, sun block, and milk use. † Analysis combined patients with FM and SLE.

![Figure 1. Mean 1,25(OH)₂-vitamin D levels and corresponding 95% CI according to patient group and HCQ use. HCQ–: no use of HCQ, HCQ+: HCQ used.](#)
were the same in both groups. This difference remained statistically significant after adjusting for age and vitamin D supplement, milk, and sun block use. These data suggest that, in SLE patients as well, HCQ inhibits the conversion of 25(OH)-vitamin D into 1,25(OH)₂-vitamin D. Theoretically, this effect could also be due to accelerated breakdown of 1,25(OH)₂-vitamin D. HCQ is known to lower lipid levels. If these longterm HCQ therapy should be checked for both their lipid levels, one also would expect lower 25(OH)-vitamin D levels; however, that was not the case in our study. Low 1,25(OH)₂-vitamin D levels might impair the efficiency of intestinal calcium absorption and contribute to a negative calcium balance by the mobilization of calcium from the bone. Three SLE patients who did use HCQ had 1,25(OH)₂-vitamin D levels < 40 pmol/l. However, their 25(OH)-vitamin D levels were normal (between 49 and 66 nmol/l).

The question arises whether patients with rheumatoid arthritis (RA) who use HCQ also have lower 1,25(OH)₂-vitamin D levels, and if this ultimately might affect bone. If this is found to be true, SLE and RA patients undergoing longterm HCQ therapy should be checked for both their 25(OH)-vitamin D and 1,25(OH)₂-vitamin D levels. If these are low, vitamin D supplementation would be advisable.

Patients using HCQ also might experience muscle weakness due to the possible direct toxic effect of HCQ on muscle. However, cases have also been described in which muscle weakness occurred in the absence of electromyographic or muscle biopsy abnormalities. In these cases HCQ might have been the cause of the muscle weakness by limiting the conversion of 25(OH)-vitamin D to 1,25(OH)₂-vitamin D.

Vitamin D plays a role not only in bone metabolism, but also in immunomodulation, as recently illustrated by the higher incidence of active tuberculosis in vitamin D deficient Gujarati Asian immigrants in London, UK. In summary, almost half our SLE and fibromyalgia patients had 25(OH)-vitamin D levels less than 50 nmol/l, at which level parathyroid hormone stimulation occurs. Our data further suggest that in patients with SLE HCQ inhibits the conversion of 25(OH)-vitamin D to 1,25(OH)₂-vitamin D, which may affect bone metabolism and immune modulation.

REFERENCES


